David C. Hastings - 08 Jan 2026 Form 4 Insider Report for Trevi Therapeutics, Inc. (TRVI)

Reporting relationship: Chief Financial Officer
Issuer ticker: TRVI
Reported as of: 08 Jan 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 12 Jan 2026, 16:05:09 UTC
Prior SEC filing: 30 Jun 2025
Next SEC filing: 30 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Christopher Galletta, attorney-in-fact

Key filing fact

David C. Hastings filed Form 4 for Trevi Therapeutics, Inc. (TRVI) on 12 Jan 2026.

Key facts

This page summarizes David C. Hastings's Form 4 filing for Trevi Therapeutics, Inc. (TRVI).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 12 Jan 2026, 16:05.

Change

Previous filing in this sequence was filed on 30 Jun 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001237401 Primary reporting owner

HASTINGS DAVID C

Relationship: Chief Financial Officer
Address: C/O TREVI THERAPEUTICS, INC., 195 CHURCH STREET, 16TH FLOOR, NEW HAVEN
Signature: /s/ Christopher Galletta, attorney-in-fact
Signature date: 12 Jan 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

TRVI transaction Derivative

Stock Option (right to buy)

Award

Transaction value: $0
Shares: +375,000
Change %
Price: $0.000000
Shares after: 375,000
Date: 08 Jan 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 375,000
Exercise price: $11.21
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

This option was granted on January 8, 2026. The 375,000 shares of common stock underlying the option are scheduled to vest as to 25% of the shares on January 8, 2027 and as to the remaining 75% of the shares in equal monthly installments thereafter through January 8, 2030.